Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

AstraZeneca PLC (LSE: AZN) Latest News

Investing Articles

AstraZeneca plc: Time To Cash In?

| Alessandro Pasetti

There are several reasons why Astra (LON:AZN) investors may want to cash in now, argues Alessandro Pasetti

Read more »

Investing Articles

What Should AstraZeneca plc Shareholders Learn From Failed Pfizer Bid?

| Roland Head

AstraZeneca plc (LON:AZN) shareholders should be happy, despite Pfizer's failure, says Roland Head.

Read more »

Investing Articles

How Much Lower Can AstraZeneca plc Go?

| Rupert Hargreaves

Will AstraZeneca plc's (LON:AZN) shares continue to fall?

Read more »

Company Comment

Lessons From The Great Investors… On Coca-Cola And AstraZeneca plc

| Mark Stones

AstraZeneca plc (LON: AZN) and Coca-Cola are the quintessential investments of two of the all-time greats.

Read more »

Company Comment

What You Need To Know About AstraZeneca plc Rejecting Pfizer’s Final Offer

| Mark Stones

AstraZeneca plc (LON: AZN) will live on as a standalone entity with ambitious revenue targets and a buzzing drugs pipeline.

Read more »

Investing Articles

Investors Should Be Careful Around AstraZeneca plc

| Rupert Hargreaves

With opposition against the Pfizer-AstraZeneca plc (LON: AZN) deal growing, investors need to be careful.

Read more »

Investing Articles

How AstraZeneca plc Could Struggle To Repeat A 5-Year Gain of 78%

| G A Chester

AstraZeneca plc (LON:AZN) could loose a third of its value in the next five years.

Read more »

Investing Articles

AstraZeneca plc Is In Play And I’m Holding Out For More

| Malcolm Wheatley

What might be the impact on your wealth if Pizfer buys AstraZeneca plc (LON:AZN)?

Read more »

Investing Articles

What Could Pfizer-AstraZeneca Be Like?

| Prabhat Sakya

What might be the positives from this potential takeover?

Read more »

Company Comment

Would A Combined AstraZeneca plc/Pfizer Inc. Be Worth Owning?

| Mark Stones

AstraZeneca plc's (LON: AZN) strengths as a separate entity won't be best harnessed by Pfizer Inc. (NYSE:PFE)

Read more »

Investing Articles

Is The Pfizer Takeover Offer for AstraZeneca plc ‘Un-American’?

| Lisa Walls-Hester

Pfizer Inc. (NYSE:PFE) has AstraZeneca plc (LON:AZN) firmly in its sights as a home for the $69bn of earnings it…

Read more »

Investing Articles

What Dividend Hunters Need To Know About AstraZeneca plc

| Royston Wild

Royston Wild looks at whether AstraZeneca plc (LON: AZN) is an attractive income stock.

Read more »